La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

PureTech Health Salute del bilancio

Salute finanziaria criteri di controllo 3/6

PureTech Health ha un patrimonio netto totale di $458.2M e un debito totale di $113.9M, che porta il suo rapporto debito/patrimonio netto a 24.8%. Le sue attività totali e le sue passività totali sono rispettivamente $694.0M e $235.7M.

Informazioni chiave

40.7%

Rapporto debito/patrimonio netto

US$124.74m

Debito

Indice di copertura degli interessi	n/a
Contanti	US$500.42m
Patrimonio netto	US$306.21m
Totale passività	US$273.74m
Totale attività	US$579.95m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

What You Need To Know About The PureTech Health plc (LON:PRTC) Analyst Downgrade Today

Aug 27

Is PureTech Health (LON:PRTC) A Risky Investment?

Apr 28

Health Check: How Prudently Does PureTech Health (LON:PRTC) Use Debt?

Dec 21

Is PureTech Health (LON:PRTC) Using Too Much Debt?

Aug 28

PureTech Health plc Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 18

We're Not So Sure You Should Rely on PureTech Health's (LON:PRTC) Statutory Earnings

Jan 18

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $347.2M ) di PRTC superano le sue passività a breve termine ( $51.4M ).

Passività a lungo termine: Le attività a breve termine di PRTC ( $347.2M ) superano le sue passività a lungo termine ( $184.4M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: PRTC ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di PRTC è aumentato da 7.2% a 24.8% negli ultimi 5 anni.

Copertura del debito: Il flusso di cassa operativo di PRTC è negativo, pertanto il debito non è ben coperto.

Copertura degli interessi: Dati insufficienti per determinare se i pagamenti degli interessi sul debito di PRTC siano ben coperti dall'EBIT.

PureTech Health Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Is PureTech Health (LON:PRTC) A Risky Investment?

Health Check: How Prudently Does PureTech Health (LON:PRTC) Use Debt?

Is PureTech Health (LON:PRTC) Using Too Much Debt?

Recent updates

PureTech Health plc Announces KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults

Consensus EPS estimates upgraded to US$0.55 loss

Consensus revenue estimates decrease by 57%

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 973%, EPS downgraded

First half 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Puretech Health plc Appoints Michele Holcomb as Independent Non-Executive Director, Effective September 23, 2024

PureTech Health plc to Report First Half, 2024 Results on Aug 28, 2024

PureTech Health plc Appoints David Wheadon to Its Board of Directors

PureTech Health plc Appoints Raju Kucherlapati as Chair of Board of Directors

PureTech Health plc (LSE:PRTC) announces an Equity Buyback for 33,500,000 shares, representing 12.37% for $100 million.

Seaport Therapeutics Announces Board of Directors Changes and Makes Key Executive Appointments

PureTech Health plc, Annual General Meeting, Jun 13, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

PureTech Health plc to Report Fiscal Year 2023 Results on Apr 25, 2024

PureTech Health plc Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis

PureTech Health plc Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers

PureTech Health plc Announces Chief Executive Officer Changes

New minor risk - Financial data availability

New major risk - Revenue and earnings growth

Puretech Health plc Presents Data from Phase 1 Trial of Lyt-200 Targeting Galectin-9 in Solid Tumors At the Esmo Immuno-Oncology Congress 2023

Puretech Health plc Announces Topline Results from Its Phase 2A, Randomized, Placebo-Controlled, Proof-Of-Concept Trial of LYT-300

PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults At Chest Annual Meeting

Puretech Announces the Appointment of Robert Lyne as Chief Portfolio Officer

Consensus revenue estimates fall by 88%

First half 2023 earnings: EPS and revenues miss analyst expectations

PureTech Health plc to Report First Half, 2023 Results on Aug 29, 2023

PureTech Health plc Receives Up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-Associated Tremor/Ataxia Syndrome

Puretech Health plc Initiates Phase 2A Clinical Trial of Lyt-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 29%

PureTech Health plc to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression

PureTech Health plc Announces Executive Changes

PureTech Health plc Announces Topline Results from the Completed, Multi-Part Phase 1 Trial of LYT-300

PureTech Health plc Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology Annual Meeting

PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform

Nektar Therapeutics (NasdaqGS:NKTR) cancelled the acquisition of PureTech Health plc (LSE:PRTC).

Nektar Therapeutics (NasdaqGS:NKTR) submitted a non-binding proposal to acquire PureTech Health plc (LSE:PRTC).

PureTech Health plc Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022

PureTech Health plc Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022

Consensus forecasts updated

What You Need To Know About The PureTech Health plc (LON:PRTC) Analyst Downgrade Today

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

PureTech Health plc to Report First Half, 2022 Results on Aug 25, 2022

PureTech Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan

PureTech Health plc Announces New Akili Data in Lupus

Puretech Health plc Announces the Initiation of A Clinical Study of LYT-100

PureTech Health plc(LSE:PRTC) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)

PureTech Health plc Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute "Long" COVID with Respiratory Complications

PureTech Health plc and Akili Interactive Labs, Inc. Appoints Matt Franklin as President and Chief Operating Officer, Effective June 21, 2022

PureTech Health plc Presents Additional Phase 1 Data for LYT-100

Consensus forecasts updated

Is PureTech Health (LON:PRTC) A Risky Investment?

Full year 2021 earnings: EPS and revenues exceed analyst expectations

PureTech Health plc, Annual General Meeting, Jun 15, 2022

Puretech Founded Entity Vedanta Biosciences Publishes Phase 1A/1B Results for Lead Program Ve303 in Cell Host & Microbe and Highlights Plann Presentations of Phase 2 Ve303 Results

PureTech Health plc Announces Publication of Research from Collaborators Demonstrating PureTech’s Glyph™ Platform Enhances Oral Absorption of Buprenorphine

PureTech Health plc to Report Fiscal Year 2021 Results on Apr 26, 2022

President recently bought UK£51k worth of stock

PureTech Health plc Announces LYT-100 Achieves 50% Reduction in Healthy Older Adults Experiencing GI-Related Adverse Events Compared to Pirfenidone

President recently bought UK£73k worth of stock

Health Check: How Prudently Does PureTech Health (LON:PRTC) Use Debt?

PureTech Health plc Reports on the Key Progress Made Across its Wholly Owned Programs 1 and Founded Entities 2 in 2021

PureTech Health plc's Lymphatic Platform Candidate Human Study

PureTech Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysfunction as a Potential Cause of and Therapeutic Target for Obesity and Insulin Resistance

Is PureTech Health (LON:PRTC) Using Too Much Debt?

Puretech Health plc Presents LYT-100 Ph1 PK & Tolerability At ERS

First half 2021 earnings released: US$0.26 loss per share (vs US$0.43 profit in 1H 2020)

President recently bought UK£83k worth of stock

PureTech Health plc Announces Additional Results from Phase 1 Study in Healthy Volunteers of VE202

President recently bought UK£69k worth of stock

PureTech Health plc (LSE:PRTC) acquired the remaining 22% stake in Alivio Therapeutics.